Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Scientific Reports|October 18, 2017
A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily membersYuan He, Peter E van Bommel, Douwe F Samplonius, et al.Blood|December 8, 2005
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemiaEdwin Bremer, Bram ten Cate, Douwe F Samplonius, et al.The Journal of Investigative Dermatology|May 26, 2019
Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint BlockadeIris Koopmans, Mark A J M Hendriks, Robert J van Ginkel, et al.Lasers in Surgery and Medicine|September 2, 2014
Photochemical internalization (PCI)-mediated enhancement of bleomycin cytotoxicity by liposomal mTHPC formulations in human head and neck cancer cellsWei Peng, Douwe F Samplonius, Sebastiaan de Visscher, et al.Oncoimmunology|December 10, 2020
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentationMark A J M Hendriks, Emily M Ploeg, Iris Koopmans, et al.Oncoimmunology|September 18, 2018
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpointIris Koopmans, Djoke Hendriks, Douwe F Samplonius, et al.Oncoimmunology|September 14, 2016
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis inductionDjoke Hendriks, Yuan He, Iris Koopmans, et al.Oncoimmunology|December 3, 2021
Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axisMark A J M Hendriks, Isabel Britsch, Xiurong Ke, et al.Journal of Molecular Medicine (Berlin, Germany)|May 28, 2008
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cellsEdwin Bremer, Marco de Bruyn, Douwe F Samplonius, et al.Oncoimmunology|May 14, 2023
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cellsIsabel Britsch, Anne P van Wijngaarden, Xiurong Ke, et al.Pageof 3